PennsaidTreatment for Osteoarthritis
Update: Pennsaid Now FDA Approved - November 4, 2009
Nuvo’s Pennsaid NDA Resubmission Accepted for Review by U.S. FDA
MISSISSAUGA, Ontario, July 13, 2006 - Nuvo Research Inc. today announced that it has resubmitted its New Drug Application (NDA) for Pennsaid, a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis of the knee to the U.S. Food and Drug Administration (FDA). The FDA has confirmed that it has received Nuvo's resubmission for review and has indicated that its goal date to complete its review of the resubmission is December 28, 2006. The resubmission is a complete Class 2 response to the deficiencies outlined in an August 2002 Non-Approvable (NA) letter issued by the FDA with respect to Pennsaid. Pennsaid is currently approved for sale in Canada and several European countries.
"This resubmission is the result of significant efforts by our employees, management and our FDA advisory board," said Dr. Henrich Guntermann, Nuvo's President and CEO. "This NDA resubmission contains data collected from recent efficacy and safety trials that were designed to answer the FDA's key concerns. If approved, Pennsaid will fill a major unmet need in the $3.7 billion U.S. osteoarthritis market."
To meet the FDA's clinical efficacy and safety requirements as stated in the NA letter, Nuvo conducted study 112, a 12-week Phase III, 5-arm, double-blind trial of 775 patients. This trial enrolled patients in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. The trial met all of its primary endpoints, being pain, physical function and patient overall health assessment. The trial also demonstrated comparable efficacy of Pennsaid to oral diclofenac.
To address the long-term safety requirements as stated in the NA letter, Nuvo conducted study 112E, a long-term multi-centre, single-arm safety study of Pennsaid applied by patients with symptoms of osteoarthritis (OA) of the knee. In total, 793 patients were treated, including 448 patients for at least six months and 116 patients for at least one year. The key observation was that long-term use did not cause any new, unexpected adverse events.
Source: Nuvo Research Inc.
Posted: July 2006
- FDA Approves Pennsaid Topical Solution - November 5, 2009
- FDA Extends Review of Pennsaid Diclofenac Sodium Topical Solution - August 5, 2009
- FDA Accepts Nuvo's Resubmission For Pennsaid - February 19, 2009
- Nuvo Provides Update on Discussions with the FDA Related toPennsaid Approval - June 19, 2007
- Nuvo Continues Discussions with the FDA Related to Pennsaid - June 6, 2007
- Nuvo announces further update on discussions with the FDA related to review of Pennsaid - March 7, 2007
- Nuvo Announces Update on Discussions With FDA Related to Approval of Pennsaid - February 9, 2007
- Nuvo Receives Approvable Letter From U.S. FDA for Pennsaid - December 29, 2006
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.